Sanchez, RAyala, RAlonso, RARibera, JGarcía, OMercadal, SMontesinos, PMartino, RBarba, PGonzález-Campos, JBarrios, MLavilla, EGil, CBernal, TEscoda, LAbella, EAmigo, MLMoreno, MJBravo, PGuàrdia, RHernández-Rivas, JMGarcía-Guiñón, APiernas, SRibera, JMMartínez-López, J2016-10-032016-10-032016-06Sanchez R, Ayala R, Alonso RA, Ribera J, García O, Mercadal S, et al. Pattern of CNS relapse in acute lymphoblastic leukemia BCR-ABL positive, the importance of characterization of ABL1 mutations in cerebrospinal fluid. Haematologica. 2016. 101 (s1) E8650390-6078http://hdl.handle.net/10668/2444He incidence of central nervous system (CNS) relapse among; patients with BCR/ABL-positive acute lymphoblastic leukemia (ALL) is 8-17%. Although tyrosine-kinase inhibitors (TKI), especially imatinib, are included in; the first-line treatment in these patients, their concentration in CNS is too low; to effectively prevent CNS relapse, making CNS prophylaxis mandatory. Aims: To study the frequency, predictors and evolution of BCR-ABL positive; ALL patients with CNS relapse in two consecutive clinical trials of the PETHEMA; group using imatinib and chemotherapy. As secondary objective we proposed; the introduction of a new method for the study of variants of uncertain; significance (VUS) in kinase domain of the BCR-ABL from cDNA of cerebrospinal; fluid (CSF) blasts, in order to adapt the TKI used in relapse according; to the clonal evolution from bone marrow (BM) to CSF cells.enMédula óseaEvolución clonalADN complementarioProteínas de fusión bcr-ablHumanosMesilato de imatinibIncidenciaMasculinoSistema nerviosoLeucemia-linfoma linfoblástico de células precursorasRecurrenciaTirosinaMedical Subject Headings::Anatomy::Hemic and Immune Systems::Immune System::Bone MarrowMedical Subject Headings::Phenomena and Processes::Cell Physiological Phenomena::Cell Physiological Processes::Clonal EvolutionMedical Subject Headings::Chemicals and Drugs::Nucleic Acids, Nucleotides, and Nucleosides::Nucleic Acids::Nucleic Acid Probes::DNA Probes::DNA, ComplementaryMedical Subject Headings::Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Transferases::Phosphotransferases::Phosphotransferases (Alcohol Group Acceptor)::Protein Kinases::Protein-Tyrosine Kinases::Proto-Oncogene Proteins c-abl::Fusion Proteins, bcr-ablMedical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::HumansMedical Subject Headings::Chemicals and Drugs::Organic Chemicals::Amides::Benzamides::Imatinib MesylateMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Morbidity::IncidenceMedical Subject Headings::Check Tags::MaleMedical Subject Headings::Anatomy::Nervous SystemMedical Subject Headings::Diseases::Hemic and Lymphatic Diseases::Lymphatic Diseases::Lymphoproliferative Disorders::Leukemia, Lymphoid::Precursor Cell Lymphoblastic Leukemia-LymphomaMedical Subject Headings::Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::RecurrenceMedical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Amino Acids::Amino Acids, Cyclic::Amino Acids, Aromatic::Tyrosineconference presentationopen access1592-8721